Meeting
2016 ASCO Annual Meeting
Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.
Authors
Thomas Aparicio
Hôpital Avicenne, AP-HP, Bobigny, France
Thomas Aparicio , Jaafar Bennouna , Karine Le Malicot , Francois Ghiringhelli , Valerie Boige , Julien Taieb , Olivier Bouche , Jean Marc Phelip , Eric Francois , Christian Borel , Roger Faroux , Jean-François Seitz , Stephane Jacquot , Dominique Genet , Faiza Khemissa , Etienne Suc , Françoise Desseigne , Patrick Texereau , Jean-Louis Jouve
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT00952029
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3531)
DOI
10.1200/JCO.2016.34.15_suppl.3531
Abstract #
3531
Poster Bd #
228
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC).
First Author: Vanessa Wong
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2016 ASCO Annual Meeting
TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.
First Author: Chiara Cremolini